MassDevice is liveblogging the MassMEDIC 11th Annual Medtech Investors Conference. We’re talking to the officers and executives of some of the hottest under-the-radar medical device firms around, finding out how and why their technologies will separate them from the pack.
CVP Diagnostics, Boston
CVP Diagnostics’ VeriCor non-invasively measures left ventricular end-diastolic pressure to help in the early detection of changes in intravascular volume.
The VeriCor monitor provides an accurate and non-invasive measurement of left ventricular end-diastolic pressure (LVEDP) that can be easily performed in the doctor’s office or hospital setting. The VeriCor monitor is useful in the early detection of changes in intravascular volume and may assist the clinician assess and diagnose the presence and severity of heart failure, target treatment, and monitor the effectiveness of medications.
- The non-invasive VeriCor monitor received 510(k) clearance from the U.S. FDA;
- The VeriCor technology is based on the observation that the arterial pressure during the strain phase of the Valsalva maneuver may directly reflect the LVEDP;
- Proprietary algorithm developed from simultaneous LVEDP measurements made in the cardiac catheterization laboratory at the same time testing with the VeriCor monitor was performed;